Search
Research
Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19Because of its beneficial off-target effects against non-mycobacterial infectious diseases, bacillus Calmette-Guérin vaccination might be an accessible early intervention to boost protection against novel pathogens. Multiple epidemiological studies and randomised controlled trials are investigating the protective effect of BCG against coronavirus disease 2019 (COVID-19).
Research
10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine versus 13-valent pneumococcal conjugate vaccine as a booster dose to broaden and strengthen protection from otitis media in Australian Aboriginal children: study protocol18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels
The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.
Research
AuTOmatic: Adaptive Trial of MessAging to improve Immunisation CoverageTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
The ORVAC Trial - A phase IV, double-blind, randomised, placebo-controlled clinical trial to optimise the delivery of RV1 rotavirus vaccine to Northern Territory Aboriginal infantsTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
BEAT-CF: Bayesian Evidence-Adaptive Tool to optimise management of Cystic FibrosisAn innovative response-adaptive approach to driving improvements in health outcomes, applied to cystic fibrosis.
Research
Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015This paper reports the results from the safety surveillance of influenza vaccines in children in Australia, in 2015.
Research
Transparent reporting of adaptive clinical trials using concurrently randomised cohortsAdaptive clinical trials have designs that evolve over time because of changes to treatments or changes to the chance that participants will receive these treatments. These changes might introduce confounding that biases crude comparisons of the treatment arms and makes the results from standard reporting methods difficult to interpret for adaptive trials. To deal with this shortcoming, a reporting framework for adaptive trials was developed based on concurrently randomised cohort reporting.
Research
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocolWe aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.
Research
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch ProtocolStaphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.